Estimated Association of a COVID-19 Diagnosis With Neurologic or Immune-Mediated Outcomes: Analysis Starting Follow-Up on the Day After Time 0.
<p>CI = confidence interval; HR = hazard ratio; NA = not applicable; NE = not estimable; RI = relative incidence; SCRI = self-controlled risk interval. Note: Encephalitis/encephalomyelitis was not evaluated with the SCRI design because of its known high case fatality rate.</p>...
שמור ב:
| מחבר ראשי: | |
|---|---|
| מחברים אחרים: | , , , , , , , , , , , , , , , , , , , , , |
| יצא לאור: |
2025
|
| נושאים: | |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|
| _version_ | 1849927640749703168 |
|---|---|
| author | Shelby S. Fisher (22676406) |
| author2 | Arnstein Lindaas (22676409) Stella G. Muthuri (5395769) Patricia C. Lloyd (18453529) Joann F. Gruber (18453535) Morgan M. Richey (21253213) Hai Lyu (22676412) Angela S. Cheng (22676415) Lisa S. Kowarski (22676418) Mollie M. McKillop (9111996) Christine Bui (21253201) Tainya C. Clarke (12892921) Jeffrey Beers (22676421) Timothy Burrell (12892927) Pablo Freyria Duenas (22676424) Yangping Chen (16549866) Minya Sheng (22676427) Richard A. Forshee (18453553) Steven A. Anderson (11865398) Yoganand Chillarige (18453556) Mary S. Anthony (13922319) Azadeh Shoaibi (11060528) J. Bradley Layton (9756019) |
| author2_role | author author author author author author author author author author author author author author author author author author author author author author |
| author_facet | Shelby S. Fisher (22676406) Arnstein Lindaas (22676409) Stella G. Muthuri (5395769) Patricia C. Lloyd (18453529) Joann F. Gruber (18453535) Morgan M. Richey (21253213) Hai Lyu (22676412) Angela S. Cheng (22676415) Lisa S. Kowarski (22676418) Mollie M. McKillop (9111996) Christine Bui (21253201) Tainya C. Clarke (12892921) Jeffrey Beers (22676421) Timothy Burrell (12892927) Pablo Freyria Duenas (22676424) Yangping Chen (16549866) Minya Sheng (22676427) Richard A. Forshee (18453553) Steven A. Anderson (11865398) Yoganand Chillarige (18453556) Mary S. Anthony (13922319) Azadeh Shoaibi (11060528) J. Bradley Layton (9756019) |
| author_role | author |
| dc.creator.none.fl_str_mv | Shelby S. Fisher (22676406) Arnstein Lindaas (22676409) Stella G. Muthuri (5395769) Patricia C. Lloyd (18453529) Joann F. Gruber (18453535) Morgan M. Richey (21253213) Hai Lyu (22676412) Angela S. Cheng (22676415) Lisa S. Kowarski (22676418) Mollie M. McKillop (9111996) Christine Bui (21253201) Tainya C. Clarke (12892921) Jeffrey Beers (22676421) Timothy Burrell (12892927) Pablo Freyria Duenas (22676424) Yangping Chen (16549866) Minya Sheng (22676427) Richard A. Forshee (18453553) Steven A. Anderson (11865398) Yoganand Chillarige (18453556) Mary S. Anthony (13922319) Azadeh Shoaibi (11060528) J. Bradley Layton (9756019) |
| dc.date.none.fl_str_mv | 2025-11-24T18:40:21Z |
| dc.identifier.none.fl_str_mv | 10.1371/journal.pone.0333704.g003 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Estimated_Association_of_a_COVID-19_Diagnosis_With_Neurologic_or_Immune-Mediated_Outcomes_Analysis_Starting_Follow-Up_on_the_Day_After_Time_0_/30698080 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Medicine Neuroscience Biotechnology Immunology Cancer Mental Health Infectious Diseases Environmental Sciences not elsewhere classified weighted hazard ratios still consistently elevated potential adverse events coronavirus disease 2019 contextualize united states 78 &# 8211 60 &# 8211 45 &# 8211 23 &# 8211 20 &# 8211 18 &# 8211 04 &# 8211 mediated adverse events vaccine safety surveillance postexposure reference windows 01 &# 8211 controlled risk interval mediated aes cannot aes included guillain xlink "> neurologic xlink "> covid xlink "> mediated conditions surveillance findings risk windows included adults 01 ). remaining aes transverse myelitis study period study observed service data relative incidences medicare fee matched comparators inverse probability increased risks increased risk generally modest data sources consistent evidence confidence intervals commercial database barré syndrome 28 ). |
| dc.title.none.fl_str_mv | Estimated Association of a COVID-19 Diagnosis With Neurologic or Immune-Mediated Outcomes: Analysis Starting Follow-Up on the Day After Time 0. |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>CI = confidence interval; HR = hazard ratio; NA = not applicable; NE = not estimable; RI = relative incidence; SCRI = self-controlled risk interval. Note: Encephalitis/encephalomyelitis was not evaluated with the SCRI design because of its known high case fatality rate.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_689e4f459f202fbad405197f468676f1 |
| identifier_str_mv | 10.1371/journal.pone.0333704.g003 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30698080 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Estimated Association of a COVID-19 Diagnosis With Neurologic or Immune-Mediated Outcomes: Analysis Starting Follow-Up on the Day After Time 0.Shelby S. Fisher (22676406)Arnstein Lindaas (22676409)Stella G. Muthuri (5395769)Patricia C. Lloyd (18453529)Joann F. Gruber (18453535)Morgan M. Richey (21253213)Hai Lyu (22676412)Angela S. Cheng (22676415)Lisa S. Kowarski (22676418)Mollie M. McKillop (9111996)Christine Bui (21253201)Tainya C. Clarke (12892921)Jeffrey Beers (22676421)Timothy Burrell (12892927)Pablo Freyria Duenas (22676424)Yangping Chen (16549866)Minya Sheng (22676427)Richard A. Forshee (18453553)Steven A. Anderson (11865398)Yoganand Chillarige (18453556)Mary S. Anthony (13922319)Azadeh Shoaibi (11060528)J. Bradley Layton (9756019)MedicineNeuroscienceBiotechnologyImmunologyCancerMental HealthInfectious DiseasesEnvironmental Sciences not elsewhere classifiedweighted hazard ratiosstill consistently elevatedpotential adverse eventscoronavirus disease 2019contextualize united states78 &# 821160 &# 821145 &# 821123 &# 821120 &# 821118 &# 821104 &# 8211mediated adverse eventsvaccine safety surveillancepostexposure reference windows01 &# 8211controlled risk intervalmediated aes cannotaes included guillainxlink "> neurologicxlink "> covidxlink ">mediated conditionssurveillance findingsrisk windowsincluded adults01 ).remaining aestransverse myelitisstudy periodstudy observedservice datarelative incidencesmedicare feematched comparatorsinverse probabilityincreased risksincreased riskgenerally modestdata sourcesconsistent evidenceconfidence intervalscommercial databasebarré syndrome28 ).<p>CI = confidence interval; HR = hazard ratio; NA = not applicable; NE = not estimable; RI = relative incidence; SCRI = self-controlled risk interval. Note: Encephalitis/encephalomyelitis was not evaluated with the SCRI design because of its known high case fatality rate.</p>2025-11-24T18:40:21ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1371/journal.pone.0333704.g003https://figshare.com/articles/figure/Estimated_Association_of_a_COVID-19_Diagnosis_With_Neurologic_or_Immune-Mediated_Outcomes_Analysis_Starting_Follow-Up_on_the_Day_After_Time_0_/30698080CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/306980802025-11-24T18:40:21Z |
| spellingShingle | Estimated Association of a COVID-19 Diagnosis With Neurologic or Immune-Mediated Outcomes: Analysis Starting Follow-Up on the Day After Time 0. Shelby S. Fisher (22676406) Medicine Neuroscience Biotechnology Immunology Cancer Mental Health Infectious Diseases Environmental Sciences not elsewhere classified weighted hazard ratios still consistently elevated potential adverse events coronavirus disease 2019 contextualize united states 78 &# 8211 60 &# 8211 45 &# 8211 23 &# 8211 20 &# 8211 18 &# 8211 04 &# 8211 mediated adverse events vaccine safety surveillance postexposure reference windows 01 &# 8211 controlled risk interval mediated aes cannot aes included guillain xlink "> neurologic xlink "> covid xlink "> mediated conditions surveillance findings risk windows included adults 01 ). remaining aes transverse myelitis study period study observed service data relative incidences medicare fee matched comparators inverse probability increased risks increased risk generally modest data sources consistent evidence confidence intervals commercial database barré syndrome 28 ). |
| status_str | publishedVersion |
| title | Estimated Association of a COVID-19 Diagnosis With Neurologic or Immune-Mediated Outcomes: Analysis Starting Follow-Up on the Day After Time 0. |
| title_full | Estimated Association of a COVID-19 Diagnosis With Neurologic or Immune-Mediated Outcomes: Analysis Starting Follow-Up on the Day After Time 0. |
| title_fullStr | Estimated Association of a COVID-19 Diagnosis With Neurologic or Immune-Mediated Outcomes: Analysis Starting Follow-Up on the Day After Time 0. |
| title_full_unstemmed | Estimated Association of a COVID-19 Diagnosis With Neurologic or Immune-Mediated Outcomes: Analysis Starting Follow-Up on the Day After Time 0. |
| title_short | Estimated Association of a COVID-19 Diagnosis With Neurologic or Immune-Mediated Outcomes: Analysis Starting Follow-Up on the Day After Time 0. |
| title_sort | Estimated Association of a COVID-19 Diagnosis With Neurologic or Immune-Mediated Outcomes: Analysis Starting Follow-Up on the Day After Time 0. |
| topic | Medicine Neuroscience Biotechnology Immunology Cancer Mental Health Infectious Diseases Environmental Sciences not elsewhere classified weighted hazard ratios still consistently elevated potential adverse events coronavirus disease 2019 contextualize united states 78 &# 8211 60 &# 8211 45 &# 8211 23 &# 8211 20 &# 8211 18 &# 8211 04 &# 8211 mediated adverse events vaccine safety surveillance postexposure reference windows 01 &# 8211 controlled risk interval mediated aes cannot aes included guillain xlink "> neurologic xlink "> covid xlink "> mediated conditions surveillance findings risk windows included adults 01 ). remaining aes transverse myelitis study period study observed service data relative incidences medicare fee matched comparators inverse probability increased risks increased risk generally modest data sources consistent evidence confidence intervals commercial database barré syndrome 28 ). |